Ondine Biomedical, Inc. OBI

Ondine Biomedical Inc (AIM:OBI, OTC:OBIMF), the developer of light-activated nasal disinfection for hospital patients, has suspended trading in its shares while it raises new investment to capitalise on its clinical and commercial progress. The company is one of a growing band of growth...

Ondine Biomedical Inc (AIM:OBI, OTC:OBIMF) has won support from Peel Hunt after partnering with Mela Solutions to accelerate access for its Steriwave infection-prevention technology across NHS intensive care units. Peel Hunt retained its ‘buy’ rating and 29p price target, highlighting the...

Ondine Biomedical Inc (AIM:OBI, OTC:OBIMF) has teamed up with Mela Solutions, whose software sits in 90% of NHS intensive care units, to help hospitals test whether its Steriwave system saves them money. Steriwave uses light to activate an antimicrobial treatment applied inside the nose,...

Ondine Biomedical Inc (AIM:OBI, OTC:OBIMF), the life sciences company, has secured the deployment of its Steriwave treatment across five hospitals in Southern Ontario. The hospitals, which serve a population of more than 3 million, will use the therapy to prevent infections in patients...

Ondine Biomedical Inc (AIM:OBI, OTC:OBIMF) President and CTO Nicolas Loebel spoke with Proactive's Stephen Gunnion about the company's photodisinfection technology, top-line results from its pivotal phase III LANTERN trial, and the commercial opportunity for Steriwave. The 5,188-patient phase III LANTERN study, conducted across 18 major US and Canadian hospitals, showed a 40.5% lower risk of 30-day surgical site infections. Loebel said the findings "change the entire nature of the company," highlighting a favourable safety profile with no device-related serious adverse events. He discussed the

Ondine Biomedical Inc (AIM:OBI, OTC:OBIMF) rose 5% to 11.50p after its phase III LANTERN trial met the primary efficacy target for reducing surgical site infections. The biotech's LANTERN trial met its prespecified primary efficacy endpoint, with the main analysis estimating a 41% reduction...

Incanthera PLC (AQSE:INC) has signed its first recurring revenue deal, supplying skincare creams to LED device maker iSmart Developments. It's a big step as the company shifts away from direct-to-consumer sales. Ondine Biomedical Inc (AIM:OBI, OTC:OBIMF) has struck a deal with Mexico's largest private hospital network to pilot its Steriwave infection treatment. Trials showed a 40% drop in post-surgical infections. Rainbow Rare Earths Ltd (LSE:RBW, OTC:RBWRF, FRA:RR1) has moved its Uberaba project in Brazil into pre-feasibility work with Mosaic. Early economics already show a $916 million net p

Ondine Biomedical Inc (AIM:OBI, OTC:OBIMF), the AIM-listed company behind light-activated antimicrobial therapies, has agreed a partnership with Hospital Ángeles, Mexico's largest private healthcare network, to pilot its Steriwave nasal photodisinfection treatment. The multi-centre pilot...

Ondine Biomedical Inc (AIM:OBI, OTC:OBIMF), the life sciences company, traded at 13.4p, up 14%, in early London trade following the release of successful phase 3 clinical trial results. Positive topline data from the LANTERN study demonstrated the efficacy of the company's nasal...

A peer-reviewed pilot study at a Canadian critical care centre marks the first deployment of nasal photodisinfection in an intensive care setting. Ondine Biomedical Inc (AIM:OBI, OTC:OBIMF) shares rose 8% to 11.85p after the company announced a peer-reviewed publication of a pilot study...

The UK market has recently faced challenges, with the FTSE 100 and FTSE 250 indices closing lower due to weak trade data from China, highlighting global economic uncertainties. Despite these broader market pressures, penny stocks remain a compelling area of interest for investors seeking opportunities in smaller or newer companies. While the term "penny stocks" may seem outdated, these investments can offer significant potential when supported by strong financials and solid growth prospects.